Back to Search Start Over

A phase II study of mitoxantrone in advanced gastric cancer

A phase II study of mitoxantrone in advanced gastric cancer

Authors :
P. O. Gill
P. Presgrave
John A. Levi
Source :
Investigational new drugs. 8(3)
Publication Year :
1990

Abstract

Sixteen patients with advanced adenocarcinoma of the stomach were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals. Nine patients had received prior chemotherapy including doxorubicin. No patients achieved either a complete or partial response, five patients had stable disease and the remainder disease progression. Moderate to severe leukopenia occurred in 10 patients with one septic death. Median survival for all patients was eight weeks (range 1–49 weeks). It is concluded that mitoxantrone has no worthwhile activity in gastric cancer at the described doses.

Details

ISSN :
01676997
Volume :
8
Issue :
3
Database :
OpenAIRE
Journal :
Investigational new drugs
Accession number :
edsair.doi.dedup.....8e0a121b80ab7629dcd1da3cbf64209e